# US 2008/0287347 A1 · Novel Lipopeptides as Antibacterial Agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0287347 A1
- Document ID: US20080287347A1
- Status: Published application
- Kind: A1
- Application number: 12/163,299
- Filed: 2008-06-27
- Published: 2008-11-20
- Earliest claimed: 1999-12-15
- Inventors: Jason Hill; Ian Parr; Michael Morytko; Jim Siedlecki; Xiang Yang Yu; Jared Silverman; Dennis Keith; John Finn; Dale Christensen; Tsvetelina Lazarova; Alan D. Watson; Yan Zhang
- Web page: https://patentgrep.com/patent/US20080287347A1

## CPC

- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- A61P 31/04: Antibacterial agents
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to novel lipopeptide compounds. The invention also relates to pharmaceutical compositions of these compounds and methods of using these compounds as antibacterial compounds. The invention also relates to methods of producing these novel lipopeptide compounds and intermediates used in producing these compounds.

## Claims

### Claim 1

A compound having the formula (I):
and salts thereof,
wherein R is:
wherein X and X″ are independently C═O, C═S, C═NH, C═NRX, S═O or SO2;
wherein n is 0 or 1;
wherein RX is alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, hydroxyl, alkoxy, carboxy or carboalkoxy;
wherein B is X″RY, H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl or heterocyclyl;
wherein RY is hydrido, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl or hydroxyl;
wherein A is H, NH2, NHRA, NRARB, alkyl, alkenyl, alkynyl, alkoxy, aryloxy, aryl, heteroaryl, cycloalkyl or heterocyclyl;
wherein RA and RB are independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl or carboalkoxy;
wherein when n is 0, then A is additionally:
wherein each of R50-R53 is independently C1-C15 alkyl;
alternatively, wherein B and A together form a 5-7 membered heterocyclic or heteroaryl ring;
wherein R1 is
wherein X′ and X″′ are independently C═O, C═S, C═NH, C═NRX′, S═O or SO2;
wherein m is 0 or 1;
wherein RX′ is alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, hydroxyl, alkoxy, carboxy or carboalkoxy;
wherein B′ is X″′RY′, H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl or heterocyclyl;
wherein RY′ is hydrido, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl or hydroxyl;
wherein A′ is H, NH2, NHRA′, NRA′RB′, heteroaryl, cycloalkyl or heterocyclyl;
wherein RA′ and RB′ are independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl or carboalkoxy;
wherein when m is 0, then A′ is additionally:
wherein each of R50-R53 is independently C1-C15 alkyl;
provided that when B′ is H and X′ is C═O, then A′ is other than
(a) a pyridinyl ring substituted with one substitutent NHC(O)RD or
(b) a C5-C6 saturated cycloalkyl ring substituted with one substitutent NHC(O)RD;
wherein RD is C1-C17 unsubstituted alkyl or C2-C17 unsubstituted alkenyl; and
when B′ is H and m=0, then A′ is not H;
wherein R2 is
wherein K and K′ together form a C3-C7 cycloalkyl or heterocyclyl ring or a C5-C10 aryl or heteroaryl ring;
wherein J is hydrido, amino, NHRJ, NRJRK, alkyl, alkenyl, alkynyl, alkoxy, aryloxy, aryl, heteroaryl, cycloalkyl, heterocyclyl, alkylamino, hydroxyl, thio, alkylthio, alkenylthio, sulfinyl, sulfonyl, azido, cyano, halo,
wherein each of R24, R25, and R26 is independently alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; or R24 and R25 together form a 5-8 membered heterocyclyl ring;
wherein RJ and RK are independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl or heterocyclyl; or
alternatively, wherein J, together with R17, forms a 5-8 membered heterocyclyl or cycloalkyl ring; or
alternatively, wherein J, together with both R17 and R18, forms a 5-8 membered aryl, cycloalkyl, heterocyclyl or heteroaryl ring; and
wherein each of R17 and R18 is independently hydrido, halo, hydroxyl, alkoxy, amino, thio, sulfinyl, sulfonyl or
or
wherein R17 and R18 taken together can form a ketal, thioketal,
wherein each of R22 and R23 is independently hydrido or alkyl.

### Claim 2

A compound having the formula (I):
and salts thereof;
wherein R is:
wherein X and X″ are independently C═O, C═S, C═NH, C═NRX, S═O or SO2;
wherein n is 0 or 1;
wherein RX is alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, hydroxyl, alkoxy, carboxy or carboalkoxy;
wherein B is X″RY, H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl or heterocyclyl;
wherein RY is hydrido, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl or hydroxyl;
wherein A is H, NH2, NHRA, NRARB, alkyl, alkenyl, alkynyl, alkoxy, aryloxy, aryl, heteroaryl, cycloalkyl or heterocyclyl;
wherein RA and RB are independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl or carboalkoxy;
wherein when n is 0, then A is additionally selected from:
wherein each of R50-R53 is independently C1-C15 alkyl;
alternatively, wherein B and A together form a 5-7 membered heterocyclic or heteroaryl ring;
wherein R1 is
wherein X′ and X″′ are independently C═O, C═S, C═NH, C═NRX′, S═O or SO2;
wherein m is 0 or 1;
wherein RX′ is alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, hydroxyl, alkoxy, carboxy or carboalkoxy;
wherein B′ is X″′RY′, H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl or heterocyclyl;
wherein RY′ is hydrido, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl or hydroxyl;
wherein A′ is aryl;
provided that when B′ is H and X′ is C═O, then A′ is other than a phenyl ring substituted with substitutent NHC(O)RD, wherein RD is C1-C17 unsubstituted alkyl or C2-C17 unsubstituted alkenyl, wherein said phenyl ring may be further optionally substituted with 1-2 substituents independently selected from amino, nitro, C1-C3 alkyl, hydroxyl, C1-C3 alkoxy, halo, mercapto, C1-C3 alkylthio, carbamyl or C1-C3 alkyl carbamyl;
wherein R2 is
wherein K and K′ together form a C3-C7 cycloalkyl or heterocyclyl ring or a C5-C10 aryl or heteroaryl ring;
wherein J is hydrido, amino, NHRJ, NRJRK, alkyl, alkenyl, alkynyl, alkoxy, aryloxy, aryl, heteroaryl, cycloalkyl, heterocyclyl, alkylamino, hydroxyl, thio, alkylthio, alkenylthio, sulfinyl, sulfonyl, azido, cyano, halo,
wherein each of R24, R25, and R26 is independently alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl; or R24 and R25 together form a 5-8 membered heterocyclyl ring;
wherein RJ and RK are independently selected from alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl or heterocyclyl; or
alternatively, wherein J, together with R17, forms a 5-8 membered heterocyclyl or cycloalkyl ring; or
alternatively, wherein J, together with both R17 and R18, forms a 5-8 membered aryl, cycloalkyl, heterocyclyl or heteroaryl ring; and
wherein each of R17 and R18 is independently hydrido, halo, hydroxyl, alkoxy, amino, thio, sulfinyl, sulfonyl or
or
wherein R17 and R18 taken together can form a ketal, thioketal,
wherein each of R22 and R23 is independently hydrido or alkyl.

### Claim 3 (depends on 1, 2)

The compound according to either of claims 1 or 2, wherein R is
wherein each of R3, R4, R5, and R6 is independently hydrido, alkyl, aryl, heterocyclyl or heteroaryl, and wherein R44 is s alkyl, aryl, heterocyclyl or heteroaryl.

### Claim 4 (depends on 3)

The compound according to claim 3, wherein R is
wherein R4′ is s alkyl, aryl-substituted alkyl, substituted phenyl, heteroaryl, heterocyclyl, optionally substituted (C8-C14)-straight chain alkyl or
wherein R7 is an alkyl group.

### Claim 5 (depends on 4)

The compound according to claim 4, wherein R is
wherein X3 is chloro or trifluoromethyl and wherein q is 0 or 1.

### Claim 6 (depends on 1, 2)

The compound according to either of claims 1 or 2, wherein R1 is
wherein each of R10 and R11 is independently hydrido, alkyl, aryl, heterocyclyl or heteroaryl; and
wherein R13 is aryl.

### Claim 7 (depends on 6)

The compound according to claim 6, wherein R1 is
wherein each of R10 and R11 is independently hydrido or alkyl; and
wherein X4 is fluoro or trifluoromethyl.

### Claim 8 (depends on 1, 2)

The compound according to either of claims 1 or 2, wherein J is hydrido, amino, azido or
wherein R17 and R18 taken together form a group selected from ketal,
or wherein R17 is hydroxyl when R18 is hydrido;
or wherein J, together with R17, forms a heterocyclyl ring.

### Claim 9 (depends on 8)

The compound according to claim 8, wherein R2 is
wherein R17 and R18 taken together form
wherein R22 is H or alkyl; and wherein R19 is hydrido, amino, azido or

### Claim 10 (depends on 9)

The compound according to claim 9, wherein R2 is

### Claim 11 (depends on 1, 2)

The compound according to either of claims 1 or 2 wherein said compound is
Cpd #
R
R1
R2
1
NHCO(CH2)8CH3
2
NHCO(CH2)8CH3
3
NHCO(CH2)8CH3
NHSO2Ph
4
NHCO(CH2)8CH3
5
NHCO(CH2)8CH3
6
NHCO(CH2)8CH3
7
NHCO(CH2)8CH3
8
NHCO(CH2)8CH3
9
NHCO(CH2)8CH3
10
NHCO(CH2)8CH3
11
NHCO(CH2)8CH3
12
NHCO(CH2)8CH3
13
NHCO(CH2)8CH3
14
NHCO(CH2)8CH3
15
NHCO(CH2)8CH3
16
NHCO(CH2)8CH3
17
NHCO(CH2)8CH3
18
NHCO(CH2)8CH3
19
NHCO(CH2)8CH3
20
NHCO(CH2)8CH3
21
NHCO(CH2)8CH3
22
NHCO(CH2)8CH3
23
NHCO(CH2)8CH3
24
NHCO(CH2)8CH3
25
NHCO(CH2)8CH3
26
NHCO(CH2)8CH3
27
NHCO(CH2)8CH3
28
NHCO(CH2)8CH3
29
NHCO(CH2)8CH3
30
NHCO(CH2)8CH3
31
NHCO(CH2)8CH3
32
NHCO(CH2)8CH3
33
NHCO(CH2)8CH3
34
NHCO(CH2)8CH3
35
NHCO(CH2)8CH3
36
NHCO(CH2)8CH3
57
NHCO(CH2)8CH3
70
NHCO(CH2)8CH3
182
NHCO(CH2)8CH3
190
NHCO(CH2)8CH3
193
NHCO(CH2)8CH3
221
NHCO(CH2)8CH3
254
NHCO(CH2)7CH3
255
NHCO(CH2)9CH3
256
NHCO(CH2)10CH3
257
NHCO(CH2)11CH3
258
NHCO(CH2)12CH3
259
NHCO(CH2)8CH3
260
NHCO(CH2)9CH3
261
NHCO(CH2)11CH3
262
NHCO(CH2)12CH3
263
270
NHCO(CH2)8CH3
292
293
NHCO(CH2)10CH3
294
NHCO(CH2)7CH3
312
NHCONH(CH2)7CH3
313
NHCONH(CH2)7CH3
314
NHCONH(CH2)10CH3
342
NHCO(CH2)9CH3
343
NHCO(CH2)10CH3
344
NHCO(CH2)12CH3
350
351
NHCO(CH2)11CH3
352
NHCONH(CH2)10CH3

### Claim 12 (depends on 11)

The compound according to claim 11 wherein the compound is
Cpd #
R
R1
R2
260
NHCO(CH2)9CH3
262
NHCO(CH2)12CH3
344
NHCO(CH2)12CH3

### Claim 13 (depends on 1, 2)

A compound of formula (I) according to either of claim 1 or claim 2, wherein R is NHCO—[(C6-C14)-alkyl]-CH3, and R1 and R2 are selected from:
R1
R2
NHSO2Ph

### Claim 14 (depends on 13)

The compound according to claim 13, wherein R is NHCO—[(CH2)6-14]-CH3.

### Claim 15 (depends on 1, 2)

A pharmaceutical composition comprising the compound according to either of claims 1 or 2 and a pharmaceutically acceptable carrier.

### Claim 16 (depends on 15)

A method of treating a bacterial infection in a subject, comprising the step of administering the pharmaceutical composition according to claim 15 to a subject in need thereof for a time and under conditions effective to ameliorate said bacterial infection.

### Claim 17 (depends on 16)

The method according to claim 16, wherein said subject is a human, an animal, a cell culture or a plant.

### Claim 18 (depends on 16)

The method according to claim 16, wherein said bacterial infection is caused by a gram-positive bacteria.

### Claim 19 (depends on 18)

The method according to claim 18, wherein said bacteria is an antibiotic-resistant bacteria.

### Claim 20 (depends on 19)

The method according to claim 19, wherein said antibiotic-resistant bacteria are resistant to vancomycin, methicillin, glycopeptide antibiotics, penicillin or daptomycin.

### Claim 21 (depends on 1, 2, 16)

The method according to claim 16, further comprising the step of co-administering more than one compound of Formula (I) according to either of claims 1 or 2 to a subject in need thereof.

### Claim 22 (depends on 16)

The method according to claim 16, further comprising the step of co-administering a second antimicrobial agent wherein said second antimicrobial agent is not included within the scope of Formula (I).

### Claim 23 (depends on 22)

The method according to claim 22, wherein said antimicrobial agent is penicillins, carbapenems, cephalosporins, aminoglycosides, bacitracin, gramicidin, mupirocin, chloramphenicol, thiamphenicol, fusidate sodium, lincomycin, clindamycin, macrolides, novobiocin, polymyxins, rifamycins, spectinomycin, tetracyclines, vancomycin, teicoplanin, streptogramins, anti-folate agents, trimethoprim, pyrimethamine, nitroimidazoles, quinolones, fluoroquinolones, isoniazid, ethambutol, pyrazinamide, para-aminosalicylic acid (PAS), cycloserine, capreomycin, ethionamide, prothionamide, thiacetazone, viomycin, everninomicin, glycopeptide, glycylcycline, ketolides, oxazolidinones, imipenen, amikacin, netilmicin, fosfomycin, gentamicin, ceftriaxone, ZIRACIN (56-deacetyl-57-demethyl-45-O-de(2-methyl-1-oxopropyl)-12-O-(2,3,6-trideoxy-3-C-methyl-4-O-methyl-3-nitro-alpha-L-arabino-hexopyranosyl)flambamycin), LY333328 (oritavancin), linezolid (N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide), SYNERCID (dalfopristin-quinupristin), aztreonam (2-[[(Z)-[1-(2-amino-4-thiazolyl)-2-[[(2S,3S)-2-methyl-4-oxo-1-sulfo-3-azetidinyl]amino]-2-oxoethylidene]amino]oxy]-2-methyl-propanoic acid), metronidazole (2-methyl-5-nitro-1H-imidazole-1-ethanol), epiroprim (5-[[3,5-diethoxy-4-(1H-pyrrol-1-yl)phenyl]methyl]-2,4-pyrimidinediamine), OCA-983 (1-[[(2S)-2-amino-3-methyl-1-oxobutyl]amino]-2,5-anhydro-3-S-[(4R,5S,6S)-2-carboxy-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-en-3-yl]-1,4-dideoxy-3-thio-D-threo-pentitol), GV-143253 (trinem), sanfetrinem((1S,5S,8aS,8bR)-1,2,5,6,7,8,8a,8b-octahydro-1-[(1R)-1-hydroxyethyl]-5-methoxy-2-oxo-azeto[2,1-a]isoindole-4-carboxylic acid), CS-834 ((4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-3-[[(3R)-5-oxo-3-pyrrolidinyl]thio]-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid (2,2-dimethyl-1-oxopropoxy)methyl ester), biapenem(6-[[(4R,5S,6S)-2-carboxy-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-en-3-yl]thio]-6,7-dihydro-5H-pyrazolo[1,2-a][1,2,4]triazol-4-ium inner salt), KA 159 (stipiamide), dynemicin A ((1S,4R,4aR,14S,14aS,18Z)-1,4,7,12,13,14-hexahydro-6,8,11-trihydroxy-3-methoxy-1-methyl-7,12-dioxo-4a,14a-epoxy-4,14-[3]hexene[1,5]diynonaphtho[2,3-c]phenanthridine-2-carboxylic acid), DX8739 ((4R,5S,6S)-3-[[(3S,5S)-5-[[4-[(2S)-5-amino-2-hydroxy-1-oxopentyl]-1-piperazinyl]carbonyl]-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid), DU 6681 ((4R,5S,6S)-3-[[(6S)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid), cefluprenam ((2E)-N-(2-amino-2-oxoethyl)-3-[(6R,7R)-7-[[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)[(fluoro methoxy)imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]-N-ethyl-N-methyl-2-propen-1-aminium inner salt), ER 35786 ((4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-3-[[(3S,5S)-5-[(R)-hydroxy(3R)-3-pyrrolidinylmethyl]-3-pyrrolidinyl]thio]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid monohydrochloride), cefoselis ((6R,7R)-7-[[(2Z)-(2-amino-4-thiazolyl)(methoxy imino)acetyl]amino]-3-[[2,3-dihydro-2-(2-hydroxyethyl)-3-imino-1H-pyrazol-1-yl]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid), sanfetrinem celexetil ((1S,5S,8aS,8bR)-1,2,5,6,7,8,8a,8b-octahydro-1-[(1R)-1-hydroxyethyl]-5-methoxy-2-oxo-azeto[2,1-a]isoindole-4-carboxylic acid 1-[(cyclohexyloxy)carbonyl]oxy]ethyl ester), cefpirome (1-[[(6R,7R)-7-[[(2Z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-6,7-dihydro-5H-cyclopenta[b]pyridinium inner salt), HMR-3647 (3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy]-11,12-dideoxy-6-O-methyl-3-oxo-12,11-[oxycarbonyl[[4-[4-(3-pyridinyl)-1H-imidazol-1-yl]butyl]imino]]-erythromycin), RU-59863 (C-7 catechol substituted cephalosporin), KP 736 ((6R,7R)-7-[[(2Z)-(2-amino-4-thiazolyl)[[(1,4-dihydro-1,5-dihydroxy-4-oxo-2-pyridinyl)methoxy]imino]acetyl]amino]-8-oxo-3-[(1,2,3-thiadiazol-5-ylthio)methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid disodium salt), Rifalazil (1′,4-didehydro-1-deoxy-1,4-dihydro-3′-hydroxy-5′-[4-(2-methylpropyl)-1-piperazinyl]-1-oxo-rifamycin VIII, MEN 10700 ((5R,6S)-3-[[(2-amino-2-oxoethyl)methylamino]methyl]-6-[(1R)-1-hydroxyethyl]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid), lenapenem ((4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-3-[[(3S,5S)-5-[(1R)-1-hydroxy-3-(methylamino)propyl]-3-pyrrolidinyl]thio]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid), BO 2502A ((4R,5S,6S)-3-[(2S,3′S,4S)-[2,3′-bipyrrolidin]-4-ylthio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid), NE-1530 (3′-sialyllacto-N-neotetraose), K130 (5-[[4-[3-[[4-[(4-aminophenyl)sulfonyl]phenyl]amino]propoxy]-3,5-dimethoxyphenyl]methyl]-2,4-pyrimidinediamine), PD 138312 ((R)-7-[3-(1-amino-1-methylethyl)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid), PD 140248 (7-[(3R)-3-[(1S)-1-aminoethyl]-1-pyrrolidinyl]-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid), CP 111905 (5-deoxy-5-[[(2E)-3-[3-hydroxy-4-(2-propenyloxy)phenyl]-2-methyl-1-oxo-2-propenyl]amino]-1,2-O-methylene-D-neo-inositol), sulopenem ((5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[[(1R,3S)-tetrahydro-1-oxido-3-thienyl]thio]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid), ritipenam acoxyl ((5R,6R)-3-[[(aminocarbonyl)oxy]methyl]-6-[(1R)-1-hydroxyethyl]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid (acetyloxy)methyl ester), RO-65-5788 ((6R,7R)-7-[[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)(hydroxyimino)acetyl]amino]-3-[(E)-[(3′R)-1′-[[(5-methyl-2-oxo-1,3-dioxol-4-yl)methoxy]carbonyl]-2-oxo[1,3′-bipyrrolidin]-3-ylidene]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid monosodium salt), Sch-40832 (N-[[48-[1-[[2,6-dideoxy-3-O-(2,6-dideoxy-D-arabino-hexopyranosyl)-D-arabino-hexopyranosyl]oxy]ethyl]-15-ethylidene-1,3a,4,5,10,11,12,13,14,15,19,20,21,22,28,29,41,42-octadecahydro-41-hydroxy-12,45-bis(1-hydroxyethyl)-1-(hydroxymethyl)-22-(1-hydroxy-1-methylpropyl)-36-methyl-51,54,57-tris(methylene)-3-(methylthio)-10,13,20,27,38,49,52,55,58-nonaoxo-18H,27H-5a,29-(iminoethaniminoethanimino ethaniminoethanimino[7,2]quinolinomethanoxy methano)-9,6:19,16:26,23:33,30-tetranitrilo-16H,33aH-imidazo[1′,5′:1,6]pyrido[3,2-m][1,11,17,24,4,7,20,27]tetrathiatetraazacyclotriacontin-1-yl]carbonyl]-2,3-didehydroalanyl-2,3-didehydro-alanine methyl ester stereoisomer), micacocidin A ((OC-6-26-A)-[(4S)-2-[(2S)-2-[(2R,4R)-2-[(4R)-4,5-dihydro-2-[2-(hydroxy-.kappa.O)-6-pentylphenyl]-4-thiazolyl-.kappa.N3]-3-methyl-4-thiazolidinyl-.kappa.N3]-2-(hydroxy-.kappa.O)-1,1-dimethylethyl]-4,5-dihydro-4-methyl-4-thiazolecarboxylato(2-)-.kappa.N3, .kappa.O4]-Zinc), SR-15402 ((1S,5S,8aS,8bR)-1,2,5,6,7,8,8a,8b-octahydro-1-[(1R)-1-hydroxyethyl]-2-oxo-5-[(3S)-3-pyrrolidinylthio]-azeto[2,1-a]isoindole-4-carboxylic acid), TOC 39 (1-(2-amino-2-oxoethyl)-4-[[(1E)-2-[(6R,7R)-7-[[(2Z)-(2-amino-4-thiazolyl)(hydroxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]ethenyl]thio]-pyridinium inner salt), carumonam ([[(Z)-[2-[[(2S,3S)-2-[[(aminocarbonyl)oxy]methyl]-4-oxo-1-sulfo-3-azetidinyl]amino]-1-(2-amino-4-thiazolyl)-2-oxoethylidene]amino]oxy]-acetic acid), cefozopran (1-[[(6R,7R)-7-[[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)(methoxy imino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-imidazo[1,2-b]pyridazinium inner salt), cefetamet pivoxil ((6R,7R)-7-[[(2Z)-(2-amino-4-thiazolyl)(methoxy imino)acetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid (2,2-dimethyl-1-oxopropoxy)methyl ester), or T 3811 (des-F(6)-quinolone).

### Claim 24 (depends on 22)

The method according to claim 22, wherein said second antimicrobial agent is imipenen, amikacin, netilmicin, fosfomycin, gentamicin, ceftriaxone, teicoplanin, Ziracin, LY333328, CL331022, HMR3647, Linezolid, Synercid, Aztreonam or Metronidazole.

### Claim 25 (depends on 17)

The method according to claim 17, wherein said subject is a human or an animal.

### Claim 26 (depends on 25)

The method according to claim 25, wherein said subject is a human.

### Claim 27 (depends on 1)

The compound of claim 1 having the formula (III):
wherein R15 is hydrido or a carbamate amino protecting group; and wherein R16 is

### Claim 28 (depends on 2)

The compound of claim 2 having the formula (III):
wherein R15 is hydrido or a carbamate amino protecting group; wherein R16 is
and wherein R57 is a halo or halo substituted alkyl group.

### Claim 29 (depends on 27, 28)

The compound according to either of claim 27 or 28 wherein said compound is
Compound #
R16
2
10
25
